Lilly scraps IL-23 psoriasis program despite phase 3 success, focuses on IBD race against...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Apr 27, 2021 at 11:02 AM.

  1. #1 cafead, Apr 27, 2021 at 11:02 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,013
    Likes Received:
    3
    via Eli Lilly has scrapped plans to seek approval for mirikizumab in psoriasis. Lilly chose not to enter the crowded market despite the anti-IL-23p19 antibody outperforming Novartis' Cosentyx in a phase 3 trial last year.

    AbbVie’s anti-IL-23 antibody Skyrizi and Johnson & Johnson’s Tremfya and Stelara, which hits IL-12 and IL-23, are already approved in plaque psoriasis. Despite trailing other anti-IL-23 drugs, Lilly moved mirikizumab into a broad phase 3 program that included three psoriasis studies, including a long-term assessment of its safety and maintenance of treatment effect.

    article source
     
    Quote

Reply to Thread